Affordable Access

Phase II evaluation of diaziquone in gastric and pancreatic cancers. A Southeastern Cancer Study Group Trial.

Authors
  • DeSimone, P
  • Kramer, B
  • Omura, G A
  • Bartolucci, A A
Type
Published Article
Journal
American Journal of Clinical Oncology
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Oct 01, 1986
Volume
9
Issue
5
Pages
401–402
Identifiers
PMID: 3776902
Source
Medline
License
Unknown

Abstract

Seventeen patients with pancreatic carcinoma and 30 patients with gastric carcinoma were treated with diaziquone on days 1 and 8 of repeated 4-week courses. No objective responses were seen. Toxicity was primarily myelosuppression, nausea, and vomiting. Since only 10 chemotherapy-naive patients were treated in each disease category, we do not regard this as a definitive trial, but our experience suggests that this dose schedule is not likely to be useful in these types of cancer.

Report this publication

Statistics

Seen <100 times